OpenAI Restricts Astra AI Over Cyberattack Risks 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
Sony, TSMC Eye $6.3 Billion Japan Chip Venture for Next-Gen Image Sensors 
Goldman Sachs Sees US Stock Buybacks Outpacing Equity Issuance as AI Funding Rises 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
ADNOC Gas Targets Up to $4B Profit in 2026 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
PLEASANTON, Calif. , Feb. 22, 2018 --
Natus Medical Incorporated (NASDAQ:BABY) announced that its Board of Directors has authorized the repurchase of up to $30 million of the Company's common stock. The expiration date is set for February 26, 2019.
The Company intends to use cash on hand, cash generated from operations, existing credit facilities or other financing to fund the share repurchase program. As of December 31, 2017, the Company had cash and cash equivalents of approximately $89 million and availability under an existing line of credit of $70 million.
The timing and amount of repurchases will be subject to applicable legal requirements including federal and state securities laws. Purchases will be made in open market transactions effected through a broker-dealer at prevailing market prices, in block trades, or in privately negotiated transactions. Shares may also be purchased pursuant to a trading plan meeting the requirements of Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, which would permit shares to be repurchased when the Company might otherwise be precluded from doing so under insider trading laws.
About Natus Medical Incorporated
Natus is a leading provider of healthcare products and services used for the screening, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, neurosurgery, epilepsy, sleep disorders, and balance and mobility disorders.
Additional information about Natus Medical can be found at www.natus.com.
Natus Medical Incorporated
Jonathan A. Kennedy
Executive Vice President and Chief Financial Officer
(925) 223-6700
[email protected]
